

J. Allen McCutchan, M.D., M.Sc.

Curriculum Vitae of 4-10-2012

Current

Position: Professor of Medicine, Emeritus (effective 6/2009)
Department of Medicine, Division of Infectious Diseases
University of California, San Diego

Office: UCSD Antiviral Research Center
220 Dickinson Street, Suite A
San Diego, CA 92103-8208

Telephone: (619) 543-8080 or (619) 543-5052 after 4:30 p.m.

Pager: (619) 290-5809

Cell: (858) 344-3085 (no messages)

Fax: (619) 543-5066

E-Mail: amccutchan@ucsd.edu

EDUCATION AND EXPERIENCE

B.A. in Chemistry (Cum Laude) 09/1960 - 08/1964
University of Evansville, Indiana

Doctorate in Medicine (M.D.) 09/1964 - 06/1968
Yale University, School of Medicine
New Haven, Connecticut

Intern and First Year Resident, Internal Medicine 07/1968 - 06/1970
Vanderbilt University, School of Medicine
Nashville, Tennessee

Captain, U.S. Army Medical Corps 07/1970 - 05/1972
Service in Vietnam, 1971-72

Second Year Resident, Internal Medicine 07/1972 - 07/1973
Yale - New Haven Hospital
New Haven, Connecticut

Research Fellow and Clinical Instructor in Medicine, 07/1973 - 07/1976
Division of Infectious Diseases, UCSD

Special Research Fellow of the NIAID 07/1974 - 06/1975

Assistant Professor of Medicine in Residence, UCSD 08/1976 - 07/1984

Scholar of the Milbank Memorial Fund, New York City 07/1980 - 07/1985

M.Sc. in Epidemiology 09/1980 - 09/1981
London School of Hygiene and Tropical Medicine
University of London

Research Associate Academic Department of Genito-Urinary Medicine, Middlesex Hospital Medical School, London	10/1981 - 08/1982
Associate Professor of Medicine in Residence, UCSD	07/1984 - 06/1991
Co-Investigator AIDS Clinical Trials Group, UCSD (NIAID) HIV Cost and Service Utilization Study, Rand Corporation	07/1986 - present 10/1994 - 07/1998
Co-Director HIV Neurobehavioral Research Center California NeuroAIDS Tissue Network CHARTER Study Fellowship Training Program, Infectious Diseases UCSD K-30 Program in Clinical Research Training (CREST/Masters of Advanced Study in Clinical Research)	06/1989 - present 10/1998 - present 10/2002 - present 07/1999 - 04/2006
Director California Collaborative (AIDS) Treatment Group UCSD Military International HIV Training Program UCSD Assistance Program for HIV to the Ethiopian Uniformed Services (Military, Police, and Prisons) (PEPFAR)	01/1986 - 06/2003 10/2002 - present 08/2005 - present
Professor of Medicine, UCSD	07/1991 - 05/2009
Professor of Medicine, Emeritus, UCSD	06/2009 - present

CERTIFICATION

Diplomate - National Board of Medical Examiners, Parts I - III	1969
Diplomate - American Board of Internal Medicine	1975
Board Certified - Internal Medicine	1975
Board Eligible - Infectious Diseases (exam not attempted)	1976

SERVICE

Chair of Committee "A", UCSD Institutional Review Board	7/1993 - 7/2002
Appointed Member, Pharmaceutical Relations Committee	11/1997 - 11/2000
Infectious Diseases Society of American Elected Member, Faculty Counsel, UCSD School of Medicine	8/2007 - present

HONORS

Special Research Fellow of NIAID	7/1974 - 7/1975
Scholar of Milbank Memorial Fund of New York	8/1980 - 8/1985
Distinguished Alumnus Award, University of Evansville, Indiana	1996
Medal of Honor, University of Evansville, Indiana	1997

PUBLICATIONS

1. **McCutchan JA**. Compartmental model for computer simulation of the control of cortisol secretion in man [Thesis]. Yale University School of Medicine, Dept. of Medicine. New Haven: Yale University, 1968.
2. Ziegler EJ, **McCutchan JA**, Douglas H, Braude AI. Prevention of lethal pseudomonas bacteremia with epimerase-deficient *E. coli* antiserum. *Trans Assoc Am Physicians*, 88:101-108, 1975.
3. **McCutchan JA**, Levine S, Braude AI. Influence of colony type on susceptibility of gonococci to killing by human serum. *J Immunol*, 116:1652-1655, 1976.
4. **McCutchan JA**, Wunderlich A, Braude AI. Role of urinary solutes in natural immunity to gonorrhea. *Infect Immun*, 15:149-155, 1977. PMC421341
5. Braude AI, Ziegler JJ, Douglas H, **McCutchan JA**. Protective properties of antisera to R core. *Microbiology*, 253-256, 1977.
6. Chunn CJ, Jones SR, **McCutchan JA**, Young EJ, Gilbert DN. Haemophilus parainfluenzae infective endocarditis. *Medicine*, 56:99-113, 1977.
7. Braude AI, Ziegler EJ, Douglas H, **McCutchan JA**. Antibody to cell wall glycolipid of gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. *J Infect Dis*, 136 (Suppl):S167-S173, 1977.
8. **McCutchan JA**, Katzenstein D, Norquist D, Chikami G, Wunderlich A, Braude AI. Role of blocking antibody in disseminated gonococcal infection. *J Immunol*, 121:181-186, 1978.
9. Corbeil LB, Wunderlich AC, **McCutchan JA**, Braude AI. Murine model of gonococcal bacteremia. *Immunobiology of Neisseria gonorrhoeae*. American Society for Microbiology; 317-318, 1978.
10. Braude AI, Corbeil LB, Levine S, Ito J, **McCutchan JA**. Possible influence of cyclic menstrual changes on resistance to the gonococcus. *Immunobiology of Neisseria gonorrhoeae*. American Society for Microbiology, 328-337, 1978.
11. McGee ZA, Melly MA, Gregg CR, Horn RG, Taylor-Robinson D, Johnson P, **McCutchan JA**. Virulence factors of gonococci: Studies using human fallopian tube organ cultures. *Immunobiology of Neisseria gonorrhoeae*. American Society for Microbiology, 258-262, 1978.
12. Corbeil LB, Wunderlich AC, Ito JI, **McCutchan JA**. Plaque assay for measuring serum bactericidal activity against gonococci. *J Clin Microbiol*, 8:618-620, 1978. PMC275307
13. **McCutchan JA**, Katzenstein D, Norquist D, Chikami G, Wunderlich A, Braude AI. Role of blocking antibody in disseminated gonococcal infection [Reprint]. *Immunobiology of Neisseria gonorrhoeae*. American Society for Microbiology, 121(5): 1884-1888, 1978.
14. Ziegler EJ, **McCutchan JA**, Braude AI. Clinical trial of core glycolipid antibody in gram-negative bacteremia. *Trans Assoc Am Physicians*, 91:253-258, 1978.
15. Braude AI, Ziegler EJ, **McCutchan JA**. Antiserum treatment of gram-negative bacteremia. *Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine*, 108:1872-1876, 1978.
16. **McCutchan JA**. Characteristics of gonococci which disseminate in the blood. *West J Med*, 49, 1978. PMC1238230

17. Berg SW, Kilpatrick ME, Harrison WO, **McCutchan JA**. Cefoxitin as a single-dose treatment for urethritis caused by penicillinase-producing *Neisseria gonorrhoeae*. *N Engl J Med*, 301:509-511, 1979.
18. Ziegler EJ, **McCutchan JA**, Braude AI. Treatment of gram-negative bacteremia with antiserum to core glycolipid. I. The experimental basis of immunity to endotoxin. *Eur J Cancer*, 15:71-76, 1979.
19. **McCutchan JA**, Ziegler EJ, Braude AI. Treatment of gram-negative bacteremia with antiserum to core glycolipid. II. A controlled trial of antiserum in patients with bacteremia. *Eur J Cancer*, 15:77-80, 1979.
20. Corbeil LB, Wunderlich AC, Corbeil RR, **McCutchan JA**, Ito Jr. JI, Braude AI. Disseminated gonococcal infection in mice. *Infect Immun*, 26:984-990, 1979. PMC414715
21. Ito JI, Jr., Corbeil LB, Wunderlich AC, **McCutchan JA**, Braude AI. Common heat stable protective antigen in gonococci. *Trans Assoc Am Physicians*, 92:160-168, 1979.
22. Wolf JL, **McCutchan JA**, Ziegler EJ, Braude AI. Prophylactic antibody to core lipopolysaccharide in neutropenia. In: *Current Chemotherapy and Infectious Disease*. American Society of Microbiology, 1439-1441, 1980.
23. Ziegler EJ, **McCutchan JA**, Douglas H, Braude AI. Successful treatment of human gram-negative bacteremia with antiserum against endotoxin core. *Trans Assoc Am Physicians*, 94:39-43, 1981.
24. **McCutchan JA**. Epidemiology of Gonorrhoeae at Subic Bay, the Philippines [Thesis]. London: University of London, 1981.
25. **McCutchan JA**. Gonorrhea and nongonococcal urethritis. In: Braude AI, ed. *Medical Microbiology and Infectious Diseases*. Philadelphia: W. B. Saunders, 1201-1210, 1981.
26. **McCutchan JA**. Gonococemia. In: Braude AI, ed. *Medical Microbiology and Infectious Diseases*. Philadelphia: W. B. Saunders, 1407-1413, 1981.
27. **McCutchan JA**. Factitious and delusional illnesses simulating infections. In: Braude AI, ed. *Medical Microbiology and Infectious Diseases*. Philadelphia: W. B. Saunders, 1860-1868, 1981.
28. Braude AI, Ziegler EJ, **McCutchan JA**, Douglas H. Immunization against nosocomial infection. *Am J Med*, 70:463-466, 1981.
29. **McCutchan JA**, Adler MW, Berrie JR. Penicillinase-producing *Neisseria gonorrhoeae* in Great Britain, 1977-81: alarming increase in incidence and recent development of endemic transmission. *Br Med J (Clin Res Ed)*, 285:337-340, 1982. PMC1498969
30. Ziegler EJ, **McCutchan JA**, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant *Escherichia coli*. *N Engl J Med*, 307:1225-1230, 1982.
31. Glauser MP, **McCutchan JA**, Ziegler EJ, Braude AI. Adjuvant therapy for severe infections. In: Klatersky J, Staquet MJ, eds. *Combination Antibiotic Therapy in the Compromised Host*. New York: Raven Press, 239-243, 1982.
32. Ziegler EJ, **McCutchan JA**, Davis CE, Braude AI. Treatment of gram-negative bacteremia with antiserum to core lipopolysaccharide. In: Weinstein L, Fields, BN, ed. *Seminars in Infectious Disease*. New York: Thieme-Stratton, 366-369, 1982.

33. Braude AI, **McCutchan JA**, Ison C, Sargeant PR. Differentiation of neisseriaceae by isoenzyme electrophoresis. *J Infect Dis*, 147:247-251, 1983.
34. Ziegler EJ, **McCutchan JA**, Braude AI. Treatment of gram-negative bacteremia with antiserum to mutant *E. coli* [Correspondence]. *N Engl J Med*, 308:1032, 1983.
35. **McCutchan JA**, Mathews WC. Acquired immune deficiency syndrome (AIDS). *West J Med*, 138:714, 1983. PMC1010803
36. Adler MW, Belsey EM, **McCutchan JA**, Mindel A. Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. *Br Med J (Clin Res Ed)*, 286:1621-1624, 1983. PMC1547923
37. **McCutchan JA**, Wolf JL, Ziegler EJ, Braude AI. Ineffectiveness of single-dose human antiserum to core glycolipid (*E. coli* J5) for prophylaxis of bacteremic, gram-negative infections in patients with prolonged neutropenia. *Schweizerische Medizinische Wochenschrift. Supplementum*, 113:40-45, 1983.
38. Braude AI, **McCutchan JA**. *Review of Medical Microbiology*. Philadelphia: W. B. Saunders, 170, 1983.
39. Payne P, Lancaster LA, Heinzman M, **McCutchan JA**. Identification of *Cryptosporidium* in patients with the acquired immunologic syndrome [Correspondence]. *N Engl J Med*, 309:613-614, 1983.
40. **McCutchan JA**, Ziegler EJ. Treatment with anti-gram-negative antibodies [Letter]. *Lancet*, 2:802-803, 1983.
41. **McCutchan JA**. Epidemiology of venereal urethritis: comparison of gonorrhoea and nongonococcal urethritis. *Rev Infect Dis*, 6:669-688, 1984.
42. Berk RN, Wall SD, McArdle CB, **McCutchan JA**, Clemett AR, Rosenblum JS, Premkumer A, Megibow AJ. Cryptosporidiosis of the stomach and small intestine in patients with AIDS. *AJR Am J Roentgenol*, 143:549-554, 1984.
43. Glauser MP, **McCutchan JA**, Ziegler E. Immunoprophylaxis and immunotherapy of gram-negative infections in the immunocompromised host. *Clin Haematol*, 13:549-555, 1984.
44. Baumgartner JD, Glauser MP, **McCutchan JA**, Ziegler EJ, van Melle G, Klauber MR, Vogt M, Muehlen E, Luethy R, Chioloro R, Geroulanos S. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. *Lancet*, 2:59-63, 1985.
45. Adler MW, **McCutchan JA**. Survey of cases of gonorrhoea caused by penicillinase producing *Neisseria gonorrhoeae* in the United Kingdom. *Genitourin Med*, 61:36-38, 1985. PMC1011752
46. **McCutchan, JA**. Antibody testing for the AIDS retrovirus—implications for clinicians. *West J Med*, 143(1):96, 1985. PMC1306243
47. Baumgartner JD, Glauser MP, Ziegler EJ, **McCutchan JA**, Klauber MR. Preventing death from shock by antibody to endotoxin core glycolipid [Letter]. *Lancet*, 2:565-566, 1985.
48. Braude A, Wunderlich A, Chikami G, Douglas H, **McCutchan A**. Generation of adherence-blocking immunoglobulin G (IgG) by vaccinating women with nonpiliated boiled gonococci: Observations on IgG binding to a high-molecular-weight protein in the outer membrane fraction. In: *Pathogenic Neisseriae: Proceedings of the Fourth International Symposium*. American Society for Microbiology, 323-328, 1985.

49. **McCutchan JA.** Gonococcal and chlamydial genital infections. In: Braude AI, Davis CE, Fierer J, eds. *Infectious Diseases and Medical Microbiology*. Philadelphia: W. B. Saunders, 1031-1038, 1986.
50. **McCutchan JA.** Gonococcemia. In: Braude AI, Davis CE, Fierer J, eds. *Infectious Diseases and Medical Microbiology*. Philadelphia: W. B. Saunders, 1195-1200, 1986.
51. **McCutchan JA.** Factitious and delusional illnesses simulating infections. In: Braude AI, ed. *Infectious Diseases and Medical Microbiology*. Philadelphia: W. B. Saunders, 1562-1568, 1986.
52. **McCutchan JA, Mathews CW.** Acquired immunodeficiency syndrome. In: Braude AI, ed. *Infectious Diseases and Medical Microbiology*. Philadelphia: W. B. Saunders, 1568-1581, 1986.
53. Tausk FA, **McCutchan A**, Spechko P, Schreiber RD, Gigli I. Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. *J Clin Invest*, 78:977-982, 1986.
54. Tausk FA, **McCutchan JA**, Schreiber RD, Spechko P, Gigli I. Deficiency of erythrocyte C3b receptor (CR1) in AIDS and AIDS-related syndromes. *Biosci Rep*, 6:81-86, 1986.
55. Ziegler MG, Echon C, Wilner KD, Spechko P, Lake CR, **McCutchan JA.** Sympathetic nervous withdrawal in the vasodepressor (vasovagal) reaction. *J Auton Nerv Syst*, 17:273-278, 1986.
56. Behar R, Wiley C, **McCutchan JA.** Cytomegalovirus polyradiculoneuropathy in acquired immune deficiency syndrome. *Neurology*, 37:557-561, 1987.
57. Fischl MA, Richman DD, Greico MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, and the AZT Collaborative Working Group (listed collaborators include **JA McCutchan**). The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. *N Engl J Med*, 317:185-191, 1987.
58. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Nusinoff-Lehrman S, and the AZT Collaborative Working Group (listed collaborators include **JA McCutchan**). Toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. *N Engl J Med*, 317:192-197, 1987.
59. Smith RS, Naso RB, Rosen J, Whalley A, Hom YL, Hoey K, Kennedy CJ, **McCutchan JA**, Spector SA, Richman DD. Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection. *J Clin Microbiol*, 25:1498-1504, 1987.
PMC269257
60. Laskin OL, Cederberg DM, Mills J, Eron LJ, Mildvan D, Spector SA, and the Ganciclovir Study Group (listed collaborators include **JA McCutchan**). Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. *Am J Med*, 83:201-207, 1987.
61. Grant I, Atkinson JH, Hesselink JR, Kennedy CJ, Richman DD, Spector SA, **McCutchan JA.** Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. *Ann Intern Med*, 107:828-836, 1987.

62. Richman DD, **McCutchan JA**, Spector SA. Detecting human immunodeficiency virus RNA in peripheral blood mononuclear cells by nucleic acid hybridization. *J Infect Dis*, 156:823-827, 1987.
63. **McCutchan JA**. Sexually transmitted disease (STD). In: Berkow R, Fletcher AJ, eds. *The Merck Manual of Diagnosis and Therapy*, 15th ed. Rahway, NJ: Merck Sharpe & Dohme Research Laboratories, 232-251, 1987.
64. **McCutchan JA**. Disturbances in newborns and infants [section on congenital syphilis]. In: Berkow R, Fletcher AJ, eds. *The Merck Manual of Diagnosis and Therapy*, 15th ed. Rahway, NJ: Merck Sharpe & Dohme Research Laboratories, 1918-1919, 1987.
65. Romano AJ, vanSonnenberg E, Casola G, Gosink BB, Withers CE, **McCutchan JA**, Leopold GR. Gallbladder and bile duct abnormalities in AIDS: sonographic findings in eight patients. *AJR Am J Roentgenol*, 150:123-127, 1988.
66. Jarvik JG, Hesselink JR, Kennedy C, Teschke R, Wiley C, Spector S, Richman D, **McCutchan JA**. Acquired immunodeficiency syndrome. Magnetic resonance patterns of brain involvement with pathologic correlation. *Arch Neurol*, 45:731-736, 1988.
67. Grant I, Atkinson JH, Hesselink JR, Kennedy CJ, Richman D, Spector S, **McCutchan A**. Central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) [Letters and Corrections]. *Ann Intern Med*, 109:508-509, 1988.
68. Grant I, Atkinson JH, Hesselink JR, Kennedy CJ, Richman DD, Spector SA, **McCutchan JA**. Human immunodeficiency virus-associated neurobehavioural disorder. *J R Coll Physicians Lond*, 22:149-157, 1988.
69. Richman DD, Andrews J, and the AZT Collaborative Working Group (listed collaborators include **JA McCutchan**). Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. *Am J Med*, 85:208-213, 1988.
70. Atkinson JH Jr, Grant I, Kennedy CJ, Richman DD, Spector SA, **McCutchan JA**. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. *Arch Gen Psychiatry*, 45:859-864, 1988.
71. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL, and the AZT Collaborative Working Group (listed collaborators include **JA McCutchan**). Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. *N Engl J Med*, 319:1573-1578, 1988.
72. Schrier RD, Gnann JW, Jr., Landes R, Lockshin C, Richman D, **McCutchan A**, Kennedy C, Oldstone MB, Nelson JA. T-cell recognition of HIV synthetic peptides in a natural infection. *J Immunol*, 142:1166-1176, 1989.
73. Spector SA, Kennedy C, **McCutchan JA**, Bozzette SA, Straube RG, Connor JD, Richman DD. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. *J Infect Dis*, 159:822-828, 1989.
74. Bentin J, Tsoukas CD, **McCutchan JA**, Spector SA, Richman DD, Vaughan JH. Impairment in T-lymphocyte responses during early infection with the human immunodeficiency virus. *J Clin Immunol*, 9:159-168, 1989.
75. Larsen RA, Bozzette S, **McCutchan JA**, Chiu J, Leal MA, Richman DD, and the California Collaborative Treatment Group. Persistent *Cryptococcus neoformans* infection of the prostate after successful treatment of meningitis. *Ann Intern Med*. 111:125-158, 1989.

76. Volberding PA, **McCutchan JA**. The HIV epidemic: medical and social challenges. *Biochimica et Biophysica Acta*, 989:227-236, 1989.
77. Dankner WM, **McCutchan JA**, Richman DD, Hirata K, Spector SA. Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization. *J Infect Dis*, 161:31-36, 1990.
78. **McCutchan JA**. Virology, immunology, and clinical course of HIV infection. *J Consult Clin Psychol*, 58:5-12, 1990.
79. Gross JG, Bozzette SA, Mathews WC, Spector SA, Abramson IS, **McCutchan JA**, Mendez T, Munguia D, Freeman WR. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. *Ophthalmology*, 97:681-686, 1990.
80. Wu AW, Benirschke K, **McCutchan JA**. Rhabdomyolysis and *Staphylococcus aureus* septicemia in a man with the acquired immunodeficiency syndrome. *West J Med*, 152:716-719, 1990. PMC1002443
81. Schrier RD, **McCutchan JA**, Venable JC, Nelson JA, Wiley CA. T-cell-induced expression of human immunodeficiency virus in macrophages. *J Virol*, 64:3280-3288, 1990. PMC249555
82. Chiu J, Nussbaum J, Bozzette S, Tilles JG, Young LS, Leedom J, Heseltine PN, **McCutchan JA**, and the California Collaborative Treatment Group. Treatment of disseminated *Mycobacterium avium* complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. *Ann Intern Med*, 113:358-361, 1990.
83. **McCutchan JA**. Four-drug regimen useful for *M avium* in AIDS. *Doctors' Infection Newsletter*, 51-52, 1990.
84. Wu AW, Mathews WC, Brysk LT, Atkinson JH, Grant I, Abramson I, Kennedy CJ, **McCutchan JA**, Spector SA, Richman DD. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. *J Acquir Immune Defic Syndr*, 3:683-690, 1990.
85. Kekow J, Wachsman W, **McCutchan JA**, Cronin M, Carson DA, Lotz M. Transforming growth factor B and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. *Proc Natl Acad Sci USA*, 87:8321-8325, 1990. PMC54947
86. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, Bartok A, Niosi J, Abramson I, Coffman J, Hughlett C, Loya R, Cassens B, Akil B, Meng T-C, Boylen CT, Nielsen D, Richman DD, Tilles JG, Leedom J, **McCutchan JA**, and the California Collaborative Treatment Group. A controlled trial of early adjunctive treatment with corticosteroids for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome. *N Engl J Med*, 323:1451-1457, 1990.
87. Masur H, Meier P, **McCutchan JA**, Feinberg J, Bernard G, Bozzette S, Clement M, Ellenberg S, Feigal D, Gagnon S, Mathews WC, Mills J, Montaner J, Nielsen O, Sattler F, Spector S, Tilles JG. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome [Special Report]. *N Engl J Med*, 323:1500-1504, 1990.
88. Sieburg HB, **McCutchan JA**, Clay OK, Cabalero L, Ostlund JJ. Simulations of HIV infection in artificial immune systems. *Physica D*. 45:208-227, 1990.

89. Jacobson DL, **McCutchan JA**, Spechko PL, Abramson I, Smith RS, Bartok A, Boss GR, Durand D, Bozzette SA, Spector SA, Richman DD. The evolution of lymphadenopathy and hypergammaglobulinemia are evidence for early and sustained polyclonal B lymphocyte activation during human immunodeficiency virus infection. *J Infect Dis*, 163:240-246, 1991.
90. Bozzette SA, Larsen RA, Chiu J, Leal MA, Jacobsen J, Rothman P, Robinson P, Gilbert G, **McCutchan JA**, Tilles J, Leedom J, Richman DD, Group atCCT. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. *N Engl J Med*, 324:580-584, 1991.
91. Dannemann BR, **McCutchan JA**, Israelski DM, Antoniskis D, Leport C, Luft BJ, Chiu J, Vildé JL, Nussbaum JN, Orellana M, Heseltine P, Leedom JM, Clumeck N, Morlat P, Remington JS, and the California Collaborative Treatment Group. Treatment of acute toxoplasmosis with intravenous clindamycin. *Eur J Clin Microbiol Infect Dis*, 10:193-195, 1991.
92. Kekow J, Wachsman W, **McCutchan JA**, Gross WL, Zachariah M, Carson DA, Lotz M. Transforming growth factor- β and suppression of humoral immune responses in HIV infection. *J Clin Invest*, 87:1010-1016, 1991. PMC329894
93. Gill PS, Rarick M, **McCutchan JA**, Slater L, Parker B, Muchmore E, Bernstein-Singer M, Akil B, Espina BM, Krailo M, Levine A. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. *Am J Med*, 90:427-433, 1991.
94. Masur H, Meier P, **McCutchan JA**, Feinberg J. Corticosteroids as adjunctive therapy for pneumocystis pneumonia in patients with AIDS [Correspondence]. *N Engl J Med*, 324: 1666-1670, 1991.
95. Bozzette SA, Larsen RA, Chiu J, Leal MA, Tilles JG, Richman DD, Leedom JM, **McCutchan JA**. Fluconazole treatment of persistent *Cryptococcus neoformans* prostatic infection in AIDS. *Ann Intern Med*, 115:285-286, 1991.
96. **McCutchan JA**. Problems of infection in organ transplantation [Review]. *Journal of the Association for Rapid Method and Automation in Microbiology*, 3:59-71, 1991.
97. Bozzette SA, Arcia J, Bartok AE, McGlynn LM, **McCutchan JA**, Richman DD, Spragg R, Spector SA. Impact of concomitant viral pathogens on the course of *Pneumocystis carinii* pneumonia. *J Protozool*, 38:183S-184S, 1991.
98. Dannemann B, **McCutchan JA**, Israelski D, Antoniskis D, Leport C, Luft B, Nussbaum J, Clumeck N, Morlat P, Chiu J, Vilde J-L, Orellana M, Feigal D, Bartok A, Heseltine P, Leedom J, Remington J, and the California Collaborative Treatment Group. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. *Ann Intern Med*, 116:33-43, 1992.
99. Day JJ, Grant I, Atkinson JH, Brysk LT, **McCutchan JA**, Hesselink JR, Heaton RK, Weinrich JD, Spector SA, Richman DD. Incidence of AIDS dementia in a two-year follow-up of AIDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort. *J Neuropsychiatry Clin Neurosci*, 4:15-20, 1992.
100. Bozzette SA, Arcia J, Bartok AE, McGlynn LM, **McCutchan JA**, Richman DD, Spector SA. Impact of *Pneumocystis carinii* and cytomegalovirus on the course and outcome of atypical pneumonia in advanced human immunodeficiency virus disease. *J Infect Dis*, 165:93-98, 1992.

101. Kemper CA, Meng TC, Nussbaum J, Chiu J, Feigal DF, Bartok AE, Leedom JM, Tilles JG, Deresinski SC, **McCutchan JA**, and the California Collaborative Treatment Group. Treatment of *Mycobacterium avium* complex bacteremia in AIDS with a four-drug oral regimen: Rifampin, ethambutol, clofazimine, and ciprofloxacin. *Ann Intern Med*, 116:466-472, 1992.
102. Darko DF, **McCutchan JA**, Kripke DF, Gillin JC, Golshan S. Fatigue, sleep disturbance, disability, and indices of progression of HIV infection. *Am J Psychiatry*, 149:514-520, 1992.
103. Bozzette SA, Feigal D, Chiu J, Gluckstein D, Kemper C, Sattler F, and the California Collaborative Treatment Group (listed collaborators include **JA McCutchan**). Length of stay and survival after intensive care for severe *Pneumocystis carinii* pneumonia: a prospective study. *Chest*, 101:1404-1406, 1992.
104. **McCutchan JA**. Sexually transmitted chlamydial and ureaplasma infections. In: Berkow R, Fletcher AJ, eds. *The Merck Manual of Diagnosis and Therapy*, 16th ed. Rahway, NJ: Merck Research Laboratories, 257-272, 1992.
105. **McCutchan JA**. Human immunodeficiency virus (HIV) infection. In: Berkow R, Fletcher AJ, eds. *The Merck Manual of Diagnosis and Therapy*, 16th ed. Rahway, NJ: Merck Research Laboratories, 77-86, 1992.
106. **McCutchan JA**. Disturbances in newborns and infants [section on congenital syphilis]. In: Berkow R, Fletcher AJ, eds. *The Merck Manual of Diagnosis and Therapy*, 16th ed. Rahway, NJ: Merck Research Laboratories, 242-245, 1992.
107. Handsfield HH, **McCutchan JA**, Corey L, Ronald AR. Special issues in clinical trials of new anti-infective drugs for the treatment of sexually transmitted diseases. *Clin Infect Dis*, 15 (Suppl 1):S96-98, 1992.
108. Corey L, **McCutchan JA**, Ronald AR, Handsfield HH. Evaluation of new anti-infective drugs for the treatment of genital infections due to herpes simplex virus. *Clin Infect Dis*, 15 (Suppl 1):S99-S107, 1992.
109. Ronald AR, Corey L, **McCutchan JA**, Handsfield HH. Evaluation of new anti-infective drugs for the treatment of chancroid. *Clin Infect Dis*, 15 (Suppl 1):S108-114, 1992.
110. **McCutchan JA**, Ronald AR, Corey L, Handsfield HH. Evaluation of new anti-infective drugs for the treatment of vaginal infections. *Clin Infect Dis*, 15 (Suppl 1):S115-S122, 1992.
111. Handsfield HH, **McCutchan JA**, Corey L, Ronald AR. Evaluation of new anti-infective drugs for the treatment of uncomplicated gonorrhea in adults and adolescents. *Clin Infect Dis*, 15 (Suppl 1):S123-S130, 1992.
112. Handsfield HH, Ronald AR, Corey L, **McCutchan JA**. Evaluation of new anti-infective drugs for the treatment of sexually transmitted chlamydial infections and related clinical syndromes. *Clin Infect Dis*, 15 (Suppl 1):S131-S139, 1992.
113. Ronald AR, Silverman M, **McCutchan JA**, Corey L, Handsfield HH. Evaluation of new anti-infective drugs for the treatment of syphilis. *Clin Infect Dis*, 15 (Suppl 1):S140-S147, 1992.
114. Wiley CA, Achim CL, Schrier RD, Heyes MP, **McCutchan JA**, Grant I. Relationship of cerebrospinal fluid immune activation associated factors to HIV encephalitis. *AIDS*, 6: 1299-1307, 1992.

115. Weinrich JD, Grant I, Jacobson DL, Robinson SR, **McCutchan JA**, and the HIV Neurobehavioral Research Center. Effects of recalled childhood gender nonconformity on adult genitoretic role and AIDS exposure. *Arch Sex Behav*, 21:559-585, 1992.
116. Gulevich SJ, Kalmijn JA, Thal LJ, Iragui-Madoz V, **McCutchan JA**, Kennedy C, Grant I, and the HIV Neurobehavioral Research Center Group. Sensory testing in human immunodeficiency virus type 1-infected men. *Arch Neurol*, 49:1281-1284, 1992.
117. **McCutchan JA**. The issue of AIDS for thoracic surgeons. In: Peters RM, Toledo JB, eds. *Perioperative Care*. Amsterdam: Elsevier Science Publishers, 165-177, 1992.
118. Chaisson R, **McCutchan JA**, Nightingale S, Young L. Managing *Mycobacterium avium* complex infection. *AIDS Clin Care*, 5:1-8, 1993.
119. Grant I, Olshen R, Atkinson JH, Heaton RK, Nelson J, **McCutchan JA**, Weinrich JD. Depressed mood does not explain neuropsychological deficits in HIV-infected persons. *Neuropsychology*, 7:53-61, 1993.
120. Patterson TL, Semple SJ, Temoshok LR, Atkinson JH, **McCutchan JA**, Straits-Tröster KA, Chandler J, Grant I. Depressive symptoms among HIV positive men: life stress, coping, and social support. *Journal of Applied Biobehavioral Research*, 1:64-87, 1993.
121. Weinrich JD, Snyder PJ, Pillard RC, Grant I, Jacobson DL, Robinson SR, **McCutchan JA**. A factor analysis of the Klein sexual orientation grid in two disparate samples. *Arch Sex Behav*, 22:157-168, 1993.
122. Jernigan TL, Archibald S, Hesselink JR, Atkinson JH, Velin RA, **McCutchan JA**, Chandler J, Grant I, and the HIV Neurobehavioral Research Center Group. Magnetic resonance imaging morphometric analysis of cerebral volume loss in human immunodeficiency virus infection. *Arch Neurol*, 50:250-255, 1993.
123. Wu AW, Rubin HR, Mathews WC, Brysk LM, Bozzette SA, Hardy WD, Atkinson JH, Grant I, Spector SA, **McCutchan JA**, Richman DD. Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. *J Acquir Immune Defic Syndr*, 6:452-458, 1993.
124. Spector SA, Hsia K, Pratt D, Lathey J, **McCutchan JA**, Alcaraz JE, Atkinson JH, Gulevich S, Wallace M, Grant I, and the HIV Neurobehavioral Research Center Group. Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid. *J Infect Dis*, 168:68-74, 1993.
125. Kornbluth RS, **McCutchan JA**. Skin test responses as predictors of tuberculous infection and of progression in HIV-infected persons [Editorial Comment]. *Ann Intern Med*, 119:241-243, 1993.
126. Gulevich SJ, **McCutchan JA**, Thal LJ, Kirson D, Durand D, Wallace M, Mehta P, Grant I. Effect of antiretroviral therapy on the cerebrospinal fluid of patients seropositive for the human immunodeficiency virus. *J Acquir Immune Defic Syndr*, 6:1002-1007, 1993.
127. Schrier RD, **McCutchan JA**, Wiley CA. Mechanisms of immune activation of human immunodeficiency virus in monocytes/macrophages. *J Virol*, 67:5713-5720, 1993.
PMC237987
128. Fantino E, Case D, Stolarz-Fantino S, Spechko P, **McCutchan JA**. Attitudes toward early detection of infection by the AIDS retrovirus among persons at high and low risk. *Bull Psychon Soc*, 31:617-620, 1993.

129. Bozzette SA, **McCutchan JA**, Spector SA, Wright B, Richman DD. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. *J Infect Dis*, 168:1374-1379, 1993.
130. **McCutchan JA**. Medical aspects of the HIV epidemic. In: Morrow WJW, Haigwood NLBB, eds. *HIV Molecular Organization, Pathogenicity and Treatment*. Amsterdam: Elsevier Science Publishers, 1-28, 1993.
131. Semple SJ, Patterson TL, Temoshok LR, **McCutchan JA**, Straits-Tröster KA, Chandler JL, Grant I, and the HIV Neurobehavioral Research Center Group. Identification of psychobiological stressors among HIV-positive women. *Women Health*, 20:15-36, 1993.
132. Kaplan RM, **McCutchan JA**, Navarro AM, Anderson JP. Quality adjusted survival analysis: a neglected application of the quality of well-being scale. *Psychol Health*, 9:131-141, 1994.
133. **McCutchan JA**. Virology, immunology, and clinical course of HIV infection. In: Grant I, Martin A, eds. *Neuropsychology of HIV Infection*. New York: Oxford University Press, 23-40, 1994.
134. **McCutchan JA**. Unproven and unconventional therapies. In: Border S, Merigan TCJ, Bolognese D, eds. *Textbook on AIDS Medicine*. Baltimore: Williams & Wilkins, 807-812, 1994.
135. Heaton RK, Velin RA, **McCutchan JA**, and the HIV Neurobehavioral Research Center Group. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. *Psychosom Med*, 56:8-17, 1994.
136. Kemper C, Havlir D, Haghigat D, Dubé M, Bartok AE, Sison JP, Yao Y, Yangco B, Leedom JM, Tilles JG, **McCutchan JA**, Deresinski SC. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on *Mycobacterium avium* complex bacteremia in patients with AIDS. *J Infect Dis*, 170:157-164, 1994.
137. Haubrich RH, Haghigat D, Bozzette SA, Tilles J, **McCutchan JA**, and the California Collaborative Treatment Group. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. *J Infect Dis*, 170:238-242, 1994.
138. Straits-Tröster KA, Patterson TL, Semple I, Roth PG, **McCutchan JA**, Chandler JL, Grant I. The relationship between loneliness, interpersonal competence and immunologic status in HIV-infected men. *Psychol Health*, 9:205-219, 1994.
139. Larsen RA, Bozzette SA, Jones BE, Haghigat D, Leal MA, Forthal D, Bauer M, Gilles JG, **McCutchan JA**, Leedom JM. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. *Clin Infect Dis*, 19:741-745, 1994.
140. Bozzette S, **McCutchan JA**, Spector SA, Richman DD. Does early zidovudine treatment prevent the emergence of syncytium-inducing human immunodeficiency virus? [Correspondence]. *J Infect Dis*, 170:1041-1042, 1994.
141. Torriani FJ, **McCutchan JA**, Bozzette SA, Grafe MR, Havlir DV. Autopsy findings in AIDS patients with *Mycobacterium avium* complex bacteremia. *J Infect Dis*, 170:1601-1605, 1994.
142. Hariharan K, Nara PL, Shabazz LA, **McCutchan JA**, Kang CY. Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals. *AIDS Res Hum Retroviruses*, 10:1629-1637, 1994.

143. Sewell DD, Jeste DV, McAdams LA, Bailey A, Harris MJ, Atkinson JH, Chandler JL, **McCutchan JA**, Grant I, and the HIV Neurobehavioral Research Center Group. Neuroleptic treatment of HIV-associated psychosis. *Neuropsychopharmacology*, 10:223-229, 1994.
144. Schrier RD, Freeman, WR, Wiley, CA, **McCutchan JA**, and the HNRC Group. CMV specific immune responses and HLA phenotypes of AIDS patients who develop CMV retinitis. *Adv Neuroimmunol*, 4:327-336, 1994.
145. Heaton RK, Velin RA, Atkinson JH, Gulevich S, **McCutchan JA**, Hesselink JR, Chandler JL, Grant I, and the HIV Neurobehavioral Research Center Group. Neuropsychological impairment in an HIV positive male cohort. In: Stein M, Baum A, eds. *Chronic Diseases*. Mahwah, NJ: Lawrence Erlbaum Associates, Inc., 1995:79-92.
146. Bozzette SA, Forthal D, Sattler FR, Kemper C, Richman DD, Tilles JG, Leedom J, **McCutchan JA**, and the California Collaborative Treatment Group. The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. *Am J Med*, 98:177-182, 1995.
147. Weinrich JD, Atkinson JH Jr, **McCutchan JA**, Grant I, and the HIV Neurobehavioral Research Center Group. Is gender dysphoria dysphoric? Elevated depression and anxiety in gender dysphoric and nondysphoric homosexual and bisexual men in an HIV sample. *Arch Sex Behav*, 24:55-72, 1995.
148. **McCutchan JA**. Cytomegalovirus infections of the nervous system in patients with AIDS. *Clin Infect Dis*, 20:747-754, 1995.
149. Schrier RD, Freeman WR, Wiley CA, **McCutchan JA**, and the HIV Neurobehavioral Research Center Group. Immune predispositions for cytomegalovirus retinitis in AIDS. *J Clin Invest*, 95:1741-1746, 1995. PMC295694
150. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, **McCutchan JA**, Taylor MJ, Kelly MD, Ellis RJ, Wolfson T, Velin R, Marcotte TD, Hesselink JR, Jernigan TL, Chandler J, Wallace M, Abramson I, and the HIV Neurobehavioral Research Center Group. The HNRC 500—Neuropsychology of HIV infection at different disease stages. *J Int Neuropsychol Soc*, 1:231-251, 1995.
151. Delis DC, Peavy G, Heaton R, Butters N, Salmon DP, Taylor M, Stout J, Mehta P, Ryan L, White D, Atkinson JH, Chandler JL, **McCutchan JA**, Grant I, and the HIV Neurobehavioral Research Center Group. Do patients with HIV-associated minor cognitive/motor disorder exhibit a "subcortical" memory profile? Evidence using the California Verbal Learning Test. *Assessment*, 2:151-165, 1995.
152. **McCutchan JA**. Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. *Clin Infect Dis*, 21 (Suppl 2):S196-S201, 1995.
153. Kirn DH, Fredericks D, **McCutchan JA**, Stites D, Shuman M. Serum ferritin levels correlate with disease activity in patients with AIDS and disseminated histoplasmosis. *Clin Infect Dis*, 21:1048-1049, 1995.
154. Kirn DH, Fredericks D, **McCutchan JA**, Stites D, Shuman M. Marked elevation of the serum ferritin is highly specific for disseminated histoplasmosis in AIDS [Letter]. *AIDS*, 9:1204-1205, 1995.

155. Weinrich JD, Atkinson JH, Patterson TL, **McCutchan JA**, Gonsiorek JC, Grant I, and the HIV Neurobehavioral Research Center Group. Associations among coping style, personality, unsafe sexual behavior, depression, conflict over sexual orientation, and gender nonconformity: HIV status as a modulating variable. *J Psychol Human Sex*, 7:135-160, 1995.
156. Patterson TL, Semple SJ, Temoshok LR, Atkinson JH, **McCutchan JA**, Straits-Tröster K, Chandler JL, Grant I, and the HIV Neurobehavioral Research Center Group. Stress and depressive symptoms prospectively predict immune change among HIV-seropositive men. *Psychiatry*, 58:299-312, 1995.
157. Darko DF, Miller JC, Gallen C, White J, Koziol J, Brown SJ, Hayduk R, Atkinson HH, Assmus J, Munnell DT, Naitoh P, **McCutchan JA**, Mitler MM. Sleep electroencephalogram delta-frequency amplitude, night plasma levels of tumor necrosis factor alpha, and human immunodeficiency virus infection. *Proc Natl Acad Sci USA*, 92:12080-12084, 1995.
158. Haubrich R, Warner J, Anderson CG, Merritt J, Jacobsen C, **McCutchan JA**, and the California Collaborative Treatment Group. Cytotoxic T lymphocyte augmentation using an HIV-1 env/rev encoding retroviral vector (HIV -IT(V)) as therapy for HIV. *Gene Ther*, 2:599-600, 1995.
159. Haubrich R, **McCutchan JA**, Holdredge R, Heiner L, Merritt J, Merchant B. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIIBenv/rev retroviral vector) in HIV-1-infected subjects. *Hum Gene Ther*, 6(7):941-955, 1995.
160. Kaplan RM, Anderson JP, Patterson TL, **McCutchan JA**, Weinrich JD, Heaton RK, Atkinson JH, Thal L, Chandler J, Grant I, and the HIV Neurobehavioral Research Center Group. Validity of the quality of well-being scale for persons with human immunodeficiency virus infection. *Psychosom Med*, 57:138-147, 1995.
161. Williams WM, Whalley AS, Comacchio RM, Rosenberg J, Watts RA, Isenberg DA, **McCutchan JA**, Morrow WJW. Correlation between expression of antibodies to histone H2B and clinical activity in HIV-infected individuals. *Clin Exp Immunol*, 104:18-24, 1996.
162. **McCutchan JA**. Azithromycin in the prophylaxis of opportunistic infections in AIDS. *Int J STD AIDS*, 7 (Suppl 1):34-37, 1996.
163. Torriani FJ, Behling CA, **McCutchan JA**, Haubrich RH, Havlir DV. Disseminated *Mycobacterium avium* complex: correlation between blood and tissue burden. *J Infect Dis*, 173:942-949, 1996.
164. Mehta P, Gulevich J, Thal LJ, Jin H, Olichney JM, **McCutchan JA**, Heaton RK, Kirson D, Kaplanski G, Atkinson JH, Wallace MR, Grant I, and the HIV Neurobehavioral Research Center Group. Neurological symptoms, not signs, are common in early HIV infection. *Journal of Neuro-AIDS*, 1:67-85, 1996.
165. Patterson TL, Shaw WS, Semple SJ, Cherner M, **McCutchan JA**, Atkinson JH, Grant I. Relationship of psychosocial factors to HIV disease progression. *Ann Behav Med*, 18:30-39, 1996.
166. Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White Jr. AC, Witt MD, Bozzette SA, **McCutchan JA**, for the California Collaborative Treatment Group. Prophylaxis against disseminated *Mycobacterium avium* complex with weekly azithromycin, daily rifabutin, or both. *N Engl J Med*, 335(6):392-398, 1996.

167. Schrier RD, Wiley CA, Spina C, **McCutchan JA**, Grant I, and the HIV Neurobehavioral Research Center Group. Pathogenic and protective correlates of T cell proliferation in AIDS. *J Clin Invest*, 98:731-740, 1996. PMC507483
168. Semple SJ, Patterson TL, Straits-Tröster K, Atkinson JH, **McCutchan JA**, Grant I, and the HIV Neurobehavioral Research Center Group. Social and psychological characteristics of HIV-infected women and gay men. *Women Health*, 24:17-41, 1996.
169. Bearer EA, Savides TJ, **McCutchan JA**. Endoscopic diagnosis and management of hepatobiliary tuberculosis. *Am J Gastroenterol*, 91:2602-2604, 1996.
170. Razani J, Murphy C, Davidson TM, Grant I, **McCutchan A**. Odor sensitivity is impaired in HIV-positive cognitively impaired patients. *Physiol Behav*, 59:877-81, 1996.
171. Arevalo JF, Quiceno JI, García RF, **McCutchan JA**, Munguia D, Nelson JA, Freeman WR. Retinal findings and characteristics in AIDS patients with systemic *Mycobacterium avium-intracellulare* complex and toxoplasmic encephalitis. *Ophthalmic Surg Lasers*, 28:50-54, 1997.
172. Ellis RJ, Deutsch R, Heaton RK, Marcotte TD, **McCutchan JA**, Nelson JA, Abramson I, Thal LJ, Atkinson JH, Wallace MR, Grant I, and the HIV Neurobehavioral Research Center Group. Neurocognitive impairment is an independent risk factor for death in HIV infection. *Arch Neurol*, 54:416-424, 1997.
173. Currier JS, **McCutchan JA**. Alternative regimens for the prophylaxis of *Mycobacterium avium* complex in acquired immune deficiency syndrome (AIDS). *Am J Med*, 102:28-31, 1997.
174. Wallace MR, Heaton RK, **McCutchan JA**, Malone JL, Velin R, Nelson J, Miller LK, Weiss PJ, Oldfield EC III, Grant I. Neurocognitive impairment in human immunodeficiency virus infection is correlated with sexually transmitted disease history. *Sex Transm Dis*, 24:398-401, 1997.
175. **McCutchan JA**. Human immunodeficiency virus infection. In: Berkow R, Beers MH, Fletcher AJ, eds. *Merck Manual: Home Edition*. Rahway, NJ: Merck & Co. Inc., 926-932, 1997.
176. **McCutchan JA**. Sexually transmitted diseases. In: Berkow R, Beers MH, Fletcher AJ, eds. *Merck Manual: Home Edition*. Rahway, NJ: Merck & Co. Inc., 937-948, 1997.
177. Mayer K, **McCutchan JA**. The newer macrolides, azalides, and streptogramins for the management of HIV-associated opportunistic infections. In: Zinner SH, Young LS, Acar JF, Neu HC, eds. *Expanding Indications for the New Macrolides, Azalides, and Streptogramins*. New York: Marcel Dekker; 257-265, 1997.
178. Dubé MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, Dezfuli MG, Bozzette SA, Bartok AE, Leedom JM, Tilles JG, **McCutchan JA**, for the California Collaborative Treatment Group. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of *Mycobacterium avium* complex bacteremia with clarithromycin-based combination therapy. *J Infect Dis*, 176:1225-1232, 1997.
179. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, **McCutchan JA**, and the HIV Neurobehavioral Research Center Group. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. *Ann Neurol*, 42:679-688, 1997.

180. Barroga CF, Ellis R, Nelson J, Heaton RK, Atkinson JH, **McCutchan JA**, Grant I, Spector SA. HIV-1 neurocognitive disorders and chemokine receptors [Correspondence]. *AIDS*, 11:1651-1652, 1997.
181. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, **McCutchan JA**, Nelson JA, Atkinson JH, Grant I, and the HIV Neurobehavioral Research Center Group. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. *Ann Neurol*, 42:963-972, 1997.
182. Goggin KJ, Zisook S, Heaton RK, Atkinson JH, Marshall S, **McCutchan JA**, Chandler JL, Grant I, and the HIV Neurobehavioral Research Center Group. Neuropsychological performance of HIV-1 infected men with major depression. *J Int Neuropsychol Soc*, 3:457-64, 1997.
183. Manly JJ, Patterson TL, Heaton RK, Semple SJ, White DA, Velin RA, Atkinson JH, **McCutchan JA**, Chandler JL, Grant I, and the HIV Neurobehavioral Research Center Group. The relationship between neuropsychological functioning and coping activity among HIV-positive men. *AIDS Behav*, 1:81-91, 1997.
184. Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wolfson T, **McCutchan JA**, Wallace MR, Atkinson JH, Grant I, and the HIV Neurobehavioral Research Center Group. Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. *Arch Neurol*, 55:161-168, 1998.
185. Havlir DV, Haubrich R, Hwang J, Dunne MW, Currier J, Forthal D, Torriani F, Richman DD, **McCutchan JA**, for the California Collaborative Treatment Group. Human immunodeficiency virus replication in AIDS patients with *Mycobacterium avium* complex bacteremia: a case control study. *J Infect Dis*, 177:595-599, 1998.
186. Ellis RJ, Seubert P, Motter R, Galasko D, Deutsch R, Heaton RK, Heyes MP, **McCutchan JA**, Atkinson JH, Grant I, and the HIV Neurobehavioral Research Center Group. Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. *Neurosci Lett*, 254:1-4, 1998.
187. **McCutchan JA**. Alternative, unconventional, and unproven therapies. In: Merigan TC, Bartlett JG, Bolognese D, eds. *Textbook of AIDS Medicine*. 2nd ed. Baltimore: Williams & Wilkins, 903-909, 1998.
188. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, Emmons CA, Senterfitt JW, Berk ML, Morton SC, Shapiro MF, for the HCSUS Consortium (listed collaborators include **JA McCutchan**). The care of HIV-infected adults in the United States. *N Engl J Med*, 339:1897-1904, 1998.
189. Havlir DV, Dubé MP, **McCutchan JA**, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Kumar PN, White AC Jr, Witt MD, Nightingale SD, Sepkowitz KA, MacGregor RR, Cheeseman SH, Torriani FJ, Zelasky MT, Sattler FR, Bozzette SA. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. *Clin Infect Dis*, 27:1369-1375, 1998.
190. Dubé MP, Torriani FJ, See D, Havlir DV, Kemper CA, Leedom JM, Tilles JG, **McCutchan JA**, Sattler FR, for the California Collaborative Treatment Group. Successful short-term suppression of clarithromycin-resistant *Mycobacterium avium* complex bacteremia in AIDS. *Clin Infect Dis*, 28:136-138, 1999.

191. Salehian B, Jacobson D, Swerdloff RS, Grafe MR, Sinha-Hikim I, **McCutchan JA**. Testicular pathologic changes and the pituitary-testicular axis during human immunodeficiency virus infection. *Endocr Pract*, 5:1-9, 1999.
192. **McCutchan JA**. Human immunodeficiency virus infection. In: Beers MH, Berkow R, eds. *The Merck Manual of Diagnosis and Therapy*, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories, 1312-1323, 1999.
193. **McCutchan JA**. Sexually transmitted diseases. In: Beers MH, Berkow R, eds. *The Merck Manual of Diagnosis and Therapy*, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories, 1323-1339, 1999.
194. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA, additional authors from the HCSUS consortium (listed authors include **JA McCutchan**). Variations in the care of HIV-infected adults in the United States: Results from the HIV cost and services utilization study. *JAMA*, 281:2305-2315, 1999.
195. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dubé MP, Hwang JY, **McCutchan JA**, and the California Collaborative Treatment Group. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. *AIDS*, 13:1099-1107, 1999.
196. Letendre SL, Lanier ER, **McCutchan JA**. Cerebrospinal fluid β chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. *J Infect Dis*, 180:310-319, 1999.
197. Dunne MW, Bozzette S, **McCutchan JA**, Dubé MP, Sattler FR, Forthal D, Kemper CA, Havlir D, for the California Collaborative Treatment Group. Efficacy of azithromycin in prevention of *Pneumocystis carinii* pneumonia: a randomized trial. *Lancet*, 354:891-895, 1999.
198. Overall IP, Heaton RK, Marcotte TD, Ellis RJ, **McCutchan JA**, Atkinson JH, Grant I, Mallory M, Masliah E, and the HIV Neurobehavioral Research Center Group. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. *Brain Pathol*, 9:209-217, 1999.
199. Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, Abramson I, Grant I, **McCutchan JA**. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. *Neurology*, 54:927-936, 2000.
200. Rosen H, Muhlestein JB, Bartlett J, Chen S, Chikami G, Corson M, Shah PK, Gurfinkel E, Handsfield H, Jackson L, Knirsch C, Kronmal R, **McCutchan JA**, Shea S. Collaborative multidisciplinary workshop report: Clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease. *J Infect Dis*, 181 (Suppl. 3): S582-S584, 2000.
201. Letendre S, Capparelli E, Ellis R, **McCutchan J**, and the HIV Neurobehavioral Research Center Group. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. *Antimicrob Agents Chemother*, 44:2173-2175, 2000. PMC90032
202. Summers J, Robinson R, Capps L, Zisook S, Atkinson JH, McCutchan E, **McCutchan JA**, Deutsch R, Patterson T, Grant I. The influence of HIV-related support groups on survival in women who lived with HIV. *Psychosomatics*, 41:262-268, 2000.

-
203. Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hafler R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, **McCutchan JA** for the ACTG 362 Study Team. Discontinuation of *Mycobacterium avium* complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. *Ann Intern Med*, 133:493-503, 2000.
 204. Mathews WC, **McCutchan JA**, Asch S, Turner BJ, Gifford AL, Kuromiya K, Brown J, Shapiro MF, Bozzette SA. National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. *Med Care*, 38(7):750-762, 2000.
 205. Kemper CA, Witt MA, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, **McCutchan JA**, Haubrich R, and the California Collaborative Treatment Group #575 Team. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. *AIDS*, 15(5):609-615, 2001.
 206. Koletar SL, Heald AE, Finkelstein D, Hafner R, Currier JS, **McCutchan JA**, Vallee M, Torriani FJ, Powderly WG, Fass RJ, Murphy RL, for the ACTG 888 Study Team. A prospective study of discontinuing primary and secondary *Pneumocystis carinii* prophylaxis after CD4+ counts increase to > 200 cells/mm³. *AIDS*, 15(12):2001.
 207. Wallace MR, Nelson JA, **McCutchan JA**, Wolfson T, Grant I, for the HNRC Group. Symptomatic HIV seroconverting illness is associated with more rapid neurological impairment. *Sex Transm Infect*, 77(3):199-201, 2001.
 208. Deutsch R, Ellis RJ, **McCutchan JA**, Marcotte TD, Letendre S, Grant I, and the HNRC Group. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. *AIDS*, 15(14):1898-1899, 2001.
 209. Wallace MR, Persing DH, **McCutchan JA**, Magara J, Nelson JA, Heaton RK, Tasker SA, Grant I, and the HNRC Group. Bartonella henselae serostatus is not correlated with neurocognitive decline in HIV infection. *Scand J Infect Dis*, 33:593-595, 2001.
 210. Haubrich RH, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dubé MP, Hwang J, Leedom JM, Tilles J, **McCutchan JA**, and the California Collaborative Treatment Group. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. *Clin Infect Dis*, 33(7):1060-1068, 2001.
 211. von Reyn CF, Williams PL, Lederman HM, **McCutchan JA**, Koletar SL, Murphy RL, Cohn SE, Evans T, Heald AE, Colquhoun D, Bassily EL, Currier JS. Skin test reactivity and cellular immune responses to *Mycobacterium avium* sensitin in AIDS patients at risk for disseminated *M. avium* infection. *Clin Diagn Lab Immunol*, 8(6):1277-1278, 2001. PMC96262
 212. Asch SM, Gifford AL, Bozzette SA, Turner B, Mathews WC, Kuromiya K, Cunningham W, Anderson R, Shapiro M, Rastegar A, **McCutchan JA**. Underuse of primary *Mycobacterium avium* complex and *Pneumocystis carinii* prophylaxis in the United States. *J Acquir Immune Defic Syndr*, 28(4):340-44, 2001.
 213. **McCutchan JA**. Data and Safety Monitoring. In: Amdur RJ, Bankert EA, eds. *Institutional Review Board Management and Function*. Boston: Jones and Bartlett Publishers, 303-305, 2002.

-
214. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, **McCutchan JA**, Grant I, Mallory ME, Hansen LA, Archibald S, Jernigan T, Masliah E, and the HNRC Group. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. *AIDS*, 16(7):1019-1029, 2002.
 215. Ellis RJ, Moore DJ, Childers ME, Letendre S, **McCutchan JA**, Wolfson T, Spector SA, Hsia K, Heaton RK, Grant I, for the HNRC Group. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. *Arch Neurol*, 59(6):923-928, 2002.
 216. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, **McCutchan JA**. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. *AIDS*, 16(15):F33-F40, 2002.
 217. Marks G, Richardson JL, Crepaz N, Stoyanoff S, Milam J, Kemper C, Larsen RA, Bolan R, Weismuller P, Hollander H, **McCutchan A**. Are HIV care providers talking with patients about safer sex and disclosure?: A multi-clinic assessment. *AIDS*, 16(14):1953-1957, 2002.
 218. Aberg JA, Chin-Hong PV, **McCutchan A**, Koletar SL, Currier JS, for the AIDS Clinical Trials Group 362 and 393 Study Teams. Localized osteomyelitis due to *Mycobacterium avium* complex in patients with human immunodeficiency virus receiving highly active antiretroviral therapy. *Clin Infect Dis*, 35(1):E8-E13, 2002.
 219. Korthuis PT, Asch S, Mancewicz M, Shapiro MF, Mathews WC, Cunningham WE, **McCutchan JA**, Gifford A, Lee ML, Bozzette SA. Measuring medication: do interviews agree with medical record and pharmacy data? *Med Care*, 40(12):1270-1282, 2002.
 220. Gonzalez R, Heaton RK, Moore DJ, Letendre S, Ellis RJ, Wolfson T, Marcotte T, Cherner M, Rippeth J, Grant I, and the HNRC Group (listed collaborators include **JA McCutchan**). Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. *J Int Neuropsychol Soc*, 9(1):64-71, 2003.
 221. Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, **McCutchan JA**, Deresinski SC. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. *J Infect Dis*, 187(8):1327-1331, 2003.
 222. **McCutchan JA**. Human immunodeficiency virus infection. In: Berkow R, Beers MH, Fletcher AJ, eds. *Merck Manual: Home Edition*, 2nd ed. Rahway, NJ: Merck & Co. Inc., 1168-1175, 2003.
 223. **McCutchan JA**. Sexually transmitted diseases. In: Berkow R, Beers MH, Fletcher AJ, eds. *Merck Manual: Home Edition*, 2nd ed. Rahway, NJ: Merck & Co. Inc., 1176-1184, 2003.
 224. Ellis RJ, Childers ME, Zimmerman JD, Frost SDW, Deutsch R, **McCutchan JA**, and the HIV Neurobehavioral Research Center Group. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy. *J Infect Dis*, 187(11):1818-1821, 2003.
 225. Hsiao A-F, Wong MD, Kanouse DE, Collins RL, Liu H, Andersen RM, Gifford AL, **McCutchan A**, Bozzette SA, Shapiro MF, Wenger NS, for the HCSUS Consortium. Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients. *J Acquir Immune Defic Syndr*, 33:157-165, 2003.

-
226. Marcotte TD, Deutsch R, **McCutchan JA**, Moore DJ, Letendre S, Ellis RJ, Wallace MR, Heaton RK, Grant I, for the San Diego HIV Neurobehavioral Research Center (HNRC) Group. Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. *Arch Neurol*, 60:1406-1412, 2003.
 227. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, **McCutchan JA**, Koletar SL, Hafner R, Connick E, Valentine FT, McElrath MJ, Roberts Jr. NJ, Currier JS, for the AIDS Clinical Trials Group 889 Study Team. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4⁺ cell depletion. *J Infect Dis*, 188:1794-1803, 2003.
 228. Langford D, Adame A, Grigorian A, Grant I, **McCutchan JA**, Ellis RJ, Marcotte TD, Masliah E, and the HIV Neurobehavioral Research Center Group. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. *J Acquir Immune Defic Syndr*, 34(5): 467-474, 2003.
 229. Asch SM, Fremont AM, Turner BJ, Gifford A, **McCutchan JA**, Mathews WMC, Bozzette SA, Shapiro MF. Symptom-based framework for assessing quality of HIV care. *Int J Qual Health Care*, 16(1):41-50, 2004.
 230. Archibald SL, Masliah E, Fennema-Notestine C, Marcotte TD, Ellis RJ, **McCutchan JA**, Heaton RK, Grant I, Mallory M, Miller A, Jernigan TL. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. *Arch Neurol*, 61(3):369-376, 2004.
 231. Freeman WR, **McCutchan JA**, Arevalo JF, Wolfson T, Marcotte TD, Heaton RK, Grant I, HNRC Group. The relationship between AIDS retinal cotton wool spots and neuropsychological impairment in HIV-positive individuals in the pre-highly active antiretroviral therapy era. *Ocul Immunol Inflamm*, 12(1):25-33, 2004. PMC1378132
 232. Milam JE, Richardson JL, Marks G, Kemper CA, **McCutchan J**. The roles of dispositional optimism and pessimism in HIV disease progression. *Psychol Health*, 19(2):167-181, 2004.
 233. Heaton RK, Marcotte TD, Rivera Mindt M, Sadek J, Moore DJ, Bentley H, **McCutchan JA**, Reicks C, Grant I, and the HNRC Group. The impact of HIV-associated neuropsychological impairment on everyday functioning. *J Int Neuropsychol Soc*, 10(3): 317-331, 2004.
 234. Richardson JL, Milam J, **McCutchan A**, Stoyanoff S, Bolan R, Weiss J, Kemper C, Larsen RA, Hollander H, Weismuller P, Chou CP, Marks G. Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment. *AIDS*, 18(8): 1179-1186, 2004.
 235. Letendre SL, **McCutchan JA**, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ, and the HNRC Group. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. *Ann Neurol*, 56(3):416-23, 2004.
 236. Richardson JL, Milam J, Stoyanoff S, Kemper C, Bolan R, Larsen RA, Weiss JM, Hollander H, Weismuller P, **McCutchan A**. Using patient risk indicators to plan prevention strategies in the clinical care setting. *J Acquir Immune Defic Syndr*, 37:S88-S94, 2004.
 237. Yasuda JM, Miller C, Currier JS, Forthal DN, Kemper CA, Beall GN, Tilles JG, Capparelli EV, **McCutchan JA**, Haubrich RH, and the California Collaborative Treatment Group (CCTG). The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. *Antivir Ther*, 9(5)753-761, 2004.

-
238. Koletar SL, Williams PL, Wu J, **McCutchan JA**, Cohn SE, Murphy RL, Lederman HM, Currier JS; AIDS Clinical Trials Group 362 Study Team. Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. *Clin Infect Dis*, 39(10):1500-1506, 2004.
 239. Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Gunthard HF, Good B, Smith DM, Wolinsky SM, Furtado M, Marquie-Beck J, Durelle J, Grant I, Richman DD, Marcotte T, **McCutchan JA**, Ellis RJ, Wong JK. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. *J Virol*, 79(3):1772-1788, 2005. PMC544082
 240. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, **McCutchan JA**, Richman DD, and the California Collaborative Treatment Group. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. *AIDS*, 19(3):295-302, 2005.
 241. **McCutchan JA**, Letendre SL. Pharmacology of antiretroviral drugs in the central nervous system: pharmacokinetics, antiretroviral resistance, and pharmacodynamics. In: Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S, eds. *The Neurology of AIDS*, 2nd ed. New York, NY: Oxford University Press, 729-734, 2005.
 242. Marks G, Richardson JL, Milam J, Bolan R, Stoyanoff S, **McCutchan A**. Use of erectile dysfunction medication and unsafe sex among HIV+ men who have sex with men in care. *Int J STD AIDS*, 16(3):271-272, 2005.
 243. Diamond C, Richardson JL, Milam J, Stoyanoff S, **McCutchan JA**, Kemper C, Larsen RA, Hollander H, Weismuller P, Bolan R; the California Collaborative Trials Group. Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. *J Acquir Immune Defic Syndr*, 39(2):211-218, 2005.
 244. Capparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, **McCutchan JA**. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. *Antimicrob Agents Chemother*, 49(6):2504-2506, 2005. PMC1140502
 245. Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, Letendre S, Videen JS, **McCutchan JA**, Patterson TL, Grant I, and the HNRC Group. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. *J Neurovirol*, 11(4):356-364, 2005.
 246. Mathews WC, Caperna JC, Barber RE, Torriani FJ, Miller LG, May S, **McCutchan JA**. Incidence of and risk factors for clinically significant methicillin-resistant staphylococcus aureus infection in a cohort of HIV-infected adults. *J Acquir Immune Defic Syndr*, 40(2):155-160, 2005.
 247. Milam J, Richardson JL, **McCutchan A**, Stoyanoff S, Weiss J, Kemper C, Larsen RA, Hollander H, Weismuller P, Bolan R. Effect of a brief antiretroviral adherence intervention delivered by HIV care providers. *J Acquir Immune Defic Syndr*, 40(3):356-363, 2005.
 248. Letendre SL, Cherner M, Ellis RJ, Gragg B, Marquie-Beck J, Gragg B, Marcotte T, Heaton RK, **McCutchan JA**, Grant I, and the HNRC Group. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. *AIDS*, 19(Suppl 3):S72-S78, 2005.
 249. de Almeida SM, Letendre S, Zimmerman J, Lazzaretto D, **McCutchan A**, Ellis R. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. *J Neuroimmunol*, 169(1-2):144-152, 2005.

-
250. **McCutchan JA**. Data and Safety Monitoring. In: Bankert EA, Amdur RJ, eds. *Institutional Review Board Management and Function*, 2nd ed. Boston: Jones and Bartlett Publishers, 262-264, 2006.
251. **McCutchan JA**. Human immunodeficiency virus. In: Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwitz M, eds. *The Merck Manual of Diagnosis and Therapy*, 18th ed. Whitehouse Station, NJ: Merck Research Laboratories, 1625-1642, 2006.
252. **McCutchan JA**. Sexually transmitted diseases. In: Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwitz M, eds. *The Merck Manual of Diagnosis and Therapy*, 18th ed. Whitehouse Station, NJ: Merck Research Laboratories, 1650-1664, 2006.
253. Langford D, Marquie-Beck J, de Almeida S, Lazzaretto D, Letendre S, Grant I, **McCutchan JA**, Masliah E, Ellis RJ, and the HIV Neurobehavioral Research Center (HNRC) Group. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. *J Neurovirol*, 12(2):100-107, 2006.
254. Pillai SK, Pond SL, Liu Y, Good BM, Strain MC, Ellis RJ, Letendre S, Smith DM, Gunthard HF, Grant I, Marcotte TD, **McCutchan JA**, Richman DD, Wong JK. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. *Brain*, 129(7):1872-1883, 2006.
255. Monteiro de Almeida S, Letendre S, Zimmerman J, Kolakowski S, Lazzaretto D, **McCutchan JA**, Ellis R. Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. *J Neuroimmunol*, 179(1-2):180-185, 2006.
256. May S, Letendre S, Haubrich R, **McCutchan JA**, Heaton R, Capparelli E, Ellis R. Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in NeuroAIDS. *J Neuroimmune Pharmacol*, 2(1):97-104, 2007.
257. Letendre SL, Marquie-Beck J, Ellis RJ, Woods SP, Best B, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, **McCutchan JA**, Morgello S, Simpson D, Alexander TJ, Durelle J, Heaton R, Grant I, The CHARTER Group. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. *J Neuroimmune Pharmacol*, 2(1):120-127, 2007.
258. **McCutchan JA**, Wu JW, Robertson K, Koletar SL, Ellis RJ, Cohn S, Taylor M, Woods S, Heaton R, Currier J, Williams PL. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. *AIDS*, 21(9):1109-1117, 2007.
259. Letendre SL, van den Brande G, Hermes A, Woods SP, Durelle J, Beck JM, **McCutchan JA**, Okamoto C, Ellis RJ, and the HIV Neurobehavioral Research Center Group. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. *Clin Infect Dis*, 45(11): 1511-1517, 2007.
260. Kozak I, Bartsch DU, Cheng L, **McCutchan A**, Weinreb RN, Freeman WR. Scanning laser polarimetry demonstration of retinal nerve fiber layer damage in human immunodeficiency virus-positive patients without infectious retinitis. *Retina*, 27(9):1267-1273, 2007.
261. Best BM, Goicoechea M, Witt MD, Miller L, Daar ES, Diamond C, Tilles JG, Kemper CA, Larsen R, Holland DT, Sun S, Jain S, Wagner G, Capparelli EV, **McCutchan JA**, Haubrich RH, and the California Collaborative Treatment Group 578 Study Team. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and experienced HIV-1-infected patients. *J Acquir Immune Defic Syndr*, 46(4):433-442, 2007.

-
262. Huang JS, Letendre S, Marquie-Beck J, Cherner M, **McCutchan JA**, Grant I, Ellis R. Low CSF leptin levels are associated with worse learning and memory performance in HIV-infected men. *J Neuroimmune Pharmacol*, 2(4):352-358, 2007.
 263. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, **McCutchan JA**, Morgello S, Simpson D, Grant I, Ellis RJ, CHARTER Group. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. *Arch Neurol*, 65(1):65-70, 2008.
 264. Letendre S, **McCutchan JA**, Ellis RJ. Neurologic complications of HIV disease and their treatment. *Top HIV Med*, 16(1):15-22, 2008.
 265. Atkinson JH, Heaton RK, Patterson TL, Wolfson T, Deutsch R, Brown SJ, Summers J, Sciolla A, Gutierrez R, Ellis RJ, Abramson I, Hesselink JR, **McCutchan JA**, Grant I; The HNRC Group. Two-year prospective study of major depressive disorder in HIV-infected men. *J Affect Disord*, 108(3):225-234, 2008.
 266. Letendre SL, **McCutchan JA**, Ellis RJ. Better biomarkers are needed to improve the management of the neurologic complications of HIV infection. *Clin Infect Dis*, 46(12):1940-1941, 2008.
 267. Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, **McCutchan JA**, Larsen RA. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. *Med Mycol*, 46(4):393-395, 2008.
 268. Goicoechea M, **McCutchan A**. Abacavir and increased risk of myocardial infarction. *Lancet*, 372(9641):803-804, 2008.
 269. Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC, Simpson DM, Ake C, Collier AC, Gelman BB, **McCutchan JA**, Morgello S, Grant I, and the CHARTER Group. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. *Ann Neurol*, 64(5):566-572, 2008.
 270. Childers ME, Woods SP, Letendre S, **McCutchan JA**, Rosario D, Grant I, Mindt MR, Ellis RJ. Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection. *J Neurovirol*, 18:1-8. 2008.
 271. Huang J, Meixner L, Fernandez S, **McCutchan JA**. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. *AIDS* 23:51-57, 2009.
 272. Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, Gelman BB, McArthur JC, **McCutchan JA**, Simpson DM, Ellis R, Capparelli EV, Grant I, for the CHARTER Group. Low atazanavir concentrations in cerebrospinal fluid. *AIDS* 23):83-87, 2009.
 273. Letendre SL, Ellis RJ, Everall I, Ances B, Bharti A, **McCutchan JA**. Neurologic complications of HIV disease and their treatment. *Top HIV Med* 17:46-56, 2009.
 274. Williams P, Wu J, Cohn S, Koletar S, **McCutchan J**, Murphy R, Currier J, for the AIDS Clinical Trials Group 362 Study Team. Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. *HIV Med*, 10:290-301, 2009.
 275. Ances BM, Bhatt A, Vaida F, Rosario D, Alexander T, Marquie-Beck J, Ellis RJ, Letendre S, Grant I, **McCutchan JA**. Role of metabolic syndrome components in human immunodeficiency virus-associated stroke. *J Neurovirol*. 26:1-8, 2009.

-
276. Atkinson JH, Higgins JA, Vigil O, Dubrow R, Remien RH, Steward WT, Casey CY, Sikkema KJ, Correale J, Ake C, McCutchan JA, Kerndt PR, Morin SF, Grant I. Psychiatric Context of Acute/Early HIV Infection. The NIMH Multisite Acute HIV Infection Study: **IV**. *AIDS Behav.* 2009 13:1061-7.
277. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, **McCutchan JA**, Heaton RK, Ellis RJ. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. *Neurology* 73(5):342-28, 2009.
278. Ances BM, Vaida F, Rosario D, Marquie-Beck J, Ellis RJ, Simpson DM, Clifford DB, McArthur JC, Grant I, **McCutchan JA**; CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Metabolic Study Group. Role of metabolic syndrome components in HIV-associated sensory neuropathy. *AIDS* 23:2317-22, 2009.
279. Mitha K, Yirsalign M, Cherner M, **McCutchan A**, Langford TD. Risk perception and beliefs regarding HIV infection among Ethiopian immigrants. *AIDS Educ Prev* 21(5):484-94, 2009.
280. **McCutchan JA** Management of HIV in resource limited settings. *Curr Opin Infect Dis.* 22:464-470, 2009.
281. Sidhu N, **McCutchan JA** Unmasking of PML by HAART: unusual clinical features and the role of IRIS. *J Neuroimmunol.* 219:100-4, 2010
282. Ances BM, Vaida F, Yeh MJ, Liang CL, Buxton RB, Letendre S, **McCutchan JA**, Ellis RJ. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. *J Infect Dis.* 201:336-40, 2010
283. de Almeida SM, Bhatt A, Riggs PK, Durelle J, Lazzaretto D, Marquie-Beck J, **McCutchan JA**, Letendre S, Ellis R. Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. *J Neurovirol.* 16:6-12, 2010
284. Kanmogne G, Kuate, C, Cysique L, Fonsah J, Eta S, Doh R, Njamnshi D , Nchindap E, Franklin D, Ellis RE, **McCutchan JA**, Binam F, Mbanya D, Heaton R, and Njamnshi A HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon *BMC Neurology*, 10:60, 2010
285. Robinson-Papp J, Morgello S, Vaida F, Fitzsimons C, Simpson DM, Elliott KJ, Al-Lozi M, Gelman BB, Clifford D, Marra CM, **McCutchan JA**, Atkinson JH, Dworkin RH, Grant I, Ellis R. Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy. *Pain.* 151:732-6.2010
286. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, **McCutchan JA**, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology* 75:2087-96 2010
287. Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, Collier A, Gelman B, Marra C, Mbeo G, **McCutchan A**, Morgello S, Simpson D, Way L, Vaida F, Ueland S, Capparelli E, Grant I; CHARTER Group Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. *Antimicrob Agents Chemother.* 2010 Dec;54(12):5156-60

-
288. Cysique LA, Franklin D Jr, Abramson I, Ellis RJ, Letendre S, Collier A, Clifford D, Gelman B, McArthur J, Morgello S, Simpson D, **McCutchan JA**, Grant I, Heaton RK. Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. *J Clin Exp Neuropsychol*. 7: 1-18 2011
 289. Reed, SL, Mamo, G, Gossa, E, Jasura, M, Getahun, M, Lemma, E, Mathews, C, and **McCutchan JA** Improved tuberculosis smear detection in resource-limited settings: Combined bleach concentration and LED fluorescence microscopy 2011 *International Health* 3:160-164
 290. Cohn SE, Jiang H, **McCutchan JA**, Koletar SL, Murphy RL, Robertson KR, de St Maurice AM, Currier JS, Williams PL Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. *AIDS Care* 1-11 2011
 291. Heaton RK, Franklin DR, Ellis RJ, **McCutchan JA**, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I; CHARTER Group; HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol*. 17:3-16 2011
 292. Banerjee S, **McCutchan JA**, Ances BM, Deutsch R, Riggs PK, Way L, Ellis RJ Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. *AIDS* 25:1-6 2011
 293. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, Gelman BB, Mbeo G, **McCutchan JA**, Simpson DM, Haubrich R, Ellis R, Grant I; on behalf of the CHARTER Group. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. *J Antimicrob Chemother*. 66:354-357 2011
 294. Lin K, Taylor MJ, Heaton R, Franklin D, Jernigan T, Fennema-Notestine C, **McCutchan A**, Atkinson JH, Ellis RJ, McArthur J, Morgello S, Simpson D, Collier AC, Marra C, Gelman B, Clifford D, Grant I. Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. *J Clin Exp Neuropsychol*. 33:326-34 2011
 295. Jernigan TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Theilmann RJ, Julaton MD, Notestine RJ, Wolfson T, Letendre SL, Ellis RJ, Heaton RK, Gamst AC, Franklin DR Jr, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, **McCutchan JA**, Morgello S, Simpson DM, Grant I; CHARTER Group. Clinical factors related to brain structure in HIV: the CHARTER study. *J Neurovirol*. 2011 Jun;17(3):248-57. Epub 2011 May 5.
 296. Byrd DA, Fellows RP, Morgello S, Franklin D, Heaton RK, Deutsch R, Atkinson JH, Clifford DB, Collier AC, Marra CM, Gelman B, **McCutchan JA**, Duarte NA, Simpson DM, McArthur J, Grant I; for the CHARTER group. Neurocognitive Impact of Substance Use in HIV Infection. *J Acquir Immune Defic Syndr*. 2011 Jun 30. [Epub ahead of print].
 297. Badiee J, Moore DJ, Atkinson JH, Vaida F, Gerard M, Duarte NA, Franklin D, Gouaux B, **McCutchan JA**, Heaton RK, McArthur J, Morgello S, Simpson D, Collier A, Marra CM, Gelman B, Clifford D, Grant I. Lifetime suicidal ideation and attempt are common among HIV+ individuals. *J Affect Disord*. 2011 Jul 22. [Epub ahead of print].
 298. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, **McCutchan JA**, Grant I; for the CHARTER Group. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. *AIDS*. 2011 Sep 10;25(14):1747-1751.

-
299. Bharti AR, Letendre SL, Wolfson T, Clifford D, Collier AC, Gelman B, McArthur J, Marra C, **McCutchan A**, Morgello S, Simpson D, Ellis RJ, Grant I. Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. *J Clin Virol*. 2011 Dec; 52(4):328-32. Epub 2011 Sep 15.
 300. Moore DJ, Arce M, Moseley S, **McCutchan JA**, Marquie-Beck J, Franklin DR, Vaida F, Achim CL, McArthur J, Morgello S, Simpson DM, Gelman BB, Collier AC, Marra CM, Clifford DB, Heaton RK, Grant I; Charter Group and HNRC Group. Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons. *J Neuropsychiatry Clin Neurosci*. 2011;23(3):316-23.
 301. Best BM, Letendre SL, Koopmans P, Rossi SS, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, **McCutchan JA**, Morgello S, Simpson DM, Capparelli EV, Ellis RJ, Grant I; the CHARTER Study Group. Low CSF Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir. *J Acquir Immune Defic Syndr*. 2012 Jan 3. [Epub ahead of print]
 302. McCutchan, JA, Marquie-Beck, J, FitzSimons, CA, Letendre, SL, Ellis, RJ R.K. Heaton, Wolfson, T, Rosario, D, Alexander, TJ, Marra, CM. Ances, B, Grant, I Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder *Neurology* 2012;78:485–492